Evidence map›Paper›PMID 40170619›Full record

ArticleEquine veterinary journal2026

Intratumoural tigilanol tiglate in the multicentre treatment of equine sarcoids and cutaneous melanomas.

Raphael Labens, Corey Saba, Jarred Williams, Anna Hollis, Jos Ensink, Eduard Jose-Cunilleras, Mireia Jordana-Garcia, Kerstin Bergvall, Mick Ruppin, Frank Condon and 6 more

Abstract readMulticenter StudyClinical Trial, Veterinary
PubMed Full text at PMC Publisher
In one paragraph

Article in Equine veterinary journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Raphael LabensCharles Sturt University, Wagga Wagga, New South Wales, Australia.ORCID https://orcid.org/0000-0002-0717-0286
Corey SabaUniversity of Georgia, Athens, Georgia, USA.ORCID https://orcid.org/0000-0003-0590-0801
Jarred WilliamsUniversity of Georgia, Athens, Georgia, USA.ORCID https://orcid.org/0000-0001-9873-0201
Anna HollisUniversity of Cambridge, Cambridge, UK.ORCID https://orcid.org/0000-0003-1954-1993
Jos EnsinkUtrecht University, Utrecht, The Netherlands.
Eduard Jose-CunillerasUniversitat Autònoma de Barcelona, Barcelona, Spain.
Mireia Jordana-GarciaUniversitat Autònoma de Barcelona, Barcelona, Spain.
Kerstin BergvallSwedish University of Agricultural Sciences, Uppsala, Sweden.ORCID https://orcid.org/0000-0002-9531-4613
Mick RuppinTableland Veterinary Service, Malanda, Queensland, Australia.
Frank CondonTableland Veterinary Service, Malanda, Queensland, Australia.
Caroline SpeltaAPIAM Animal Health, Clermont, Queensland, Australia.
Yvonne ElceAtlantic Veterinary College, University of Prince Edward Island, Charlottetown, Prince Edward Island, Canada.ORCID https://orcid.org/0000-0002-0417-3190
Thomas De RidderQBiotics Group, Brisbane, Queensland, Australia.ORCID https://orcid.org/0000-0003-2628-5684
John MortonJemora Consulting, Geelong, Victoria, Australia.
Cassandra McGeeQBiotics Group, Brisbane, Queensland, Australia.
Paul ReddellQBiotics Group, Brisbane, Queensland, Australia.ORCID https://orcid.org/0000-0002-0993-8957

Funding

QBiotics Group Limited
6 · The paper itself

Abstract

backgroundIntralesional chemotherapeutic administration represents an important treatment option for equine cutaneous neoplasia. Tigilanol-tiglate (TT), a novel molecule extracted from Fontainea picrosperma, an Australian rainforest plant, is registered for intratumoural treatment of canine MCT, leading to rapid oncosis and tumour slough. Evidence from horses is limited but suggests that efficacy may be similar.

objectivesTo evaluate the response to intratumoural TT treatment in horses with sarcoids (fibroblastic/nodular) and cutaneous melanomas. STUDY

designTwo noncontrolled prospective multicentre clinical trials, one for each of sarcoids and melanomas.

methodsCases were enrolled across multiple sites and treated by the same site-specific clinician with intralesional TT (sarcoids: 0.35 mg/cm

resultsForty-one sarcoids and 97 melanomas were enrolled and treated. 73/74% of treated sarcoids/melanomas showed complete T MAIN LIMITATIONS: Lack of treatment control and histologic/biomolecular follow-up data.

conclusionsThe observed therapeutic efficacy of TT supports clinical use as well as early interventions in horses. Successful use necessitates knowledge of the drug's mode of action and management of associated local site responses.

Indexed as

Antineoplastic AgentsHorse DiseasesMelanomaSkin NeoplasmsAnimalsFemaleHorsesInjections, IntralesionalMaleProspective StudiesAntineoplastic Agentshorseneoplasiaskinstelfonta

Identifiers

PMID40170619
PMCPMC12699102

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.